Tony Siu

This inventor holds 21 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 14 EPO patents, primarily in Immunotherapy Compounds. Top assignees: Merck Sharp + Dohme Corp., Merck Canada Inc., Merck + Co., Inc.. Active years: 2009-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tony Siu. Retrieved from https://idiyas.com/inventor/tony-siu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 7)

% Patents Active = 85.7

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 14 (Patent Applications = 20)

Average Co-Inventor Count = 11.2

ph-index = 6

Forward Citations = 100(Granted Patents)

Company Filing History:

20 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2009-2023

Loading Chart...

Areas of Expertise:

RIG-I Agonists

STING Inhibitors

Cyclic Di-Nucleotide

Benzo[b]thiophene

Btk Inhibitors

Janus Kinase

Syk Inhibitors

Akt Activity

Pyrazole Carboxamides

Aminopyrimidines

Cyanomethylpyrazole

Indazole Compounds

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11542505 - Substituted RIG-I agonists: compositions and methods thereof (2023-01-03),

2. 11311528 - Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors (2022-04-26),

3. 10766919 - Cyclic di-nucleotide compounds as sting agonists (2020-09-08),

4. 10738074 - Cyclic di-nucleotide compounds as STING agonists (2020-08-11),

5. 10730849 - Benzo[b]thiophene compounds as STING agonists (2020-08-04),

6. 10703738 - Benzo[b]thiophene compounds as STING agonists (2020-07-07),

7. 10414747 - Benzo[b]thiophene compounds as sting agonists (2019-09-17),

8. 10246457 - Indazole and azaindazole Btk inhibitors (2019-04-02),

9. 10106574 - Cyclic di-nucleotide compounds as sting agonists (2018-10-23),

10. 9394282 - Pyrazole carboxamides as Janus kinase inhibitors (2016-07-19),

11. 9328099 - Cyanomethylpyrazole carboxamides as janus kinase inhibitors (2016-05-03),

12. 9242984 - Pyrazolyl derivatives as Syk inhibitors (2016-01-26),

13. 8962608 - Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors (2015-02-24),

14. 8614221 - Inhibitors of Akt activity (2013-12-24),

15. 8551984 - Aminopyrimidines as SYK inhibitors (2013-10-08),

Title: An Insight into the Innovations of Tony Siu

Introduction

Tony Siu, based in Brookline, MA, is a prolific inventor with a remarkable portfolio of 21 patents. His work primarily focuses on groundbreaking contributions to the fields of biochemistry and pharmacology. Through his innovative inventions, he has aimed at tackling significant health issues, such as inflammation and cancer.

Latest Patents

Two of his latest patents showcase his cutting-edge research. The first patent, titled "Substituted RIG-I Agonists: Compositions and Methods Thereof," provides valuable compositions, compounds, and uses thereof. This invention revolves around single-strand oligonucleotides that can form short hairpin structures to bind and activate the RIG-I pathway, potentially offering new therapeutic avenues. The second patent, "Oxo-Tetrahydro-Isoquinoline Carboxylic Acids as STING Inhibitors," introduces compounds that function as STING inhibitors. These compounds are particularly useful in treating STING-mediated diseases, including inflammation, asthma, Chronic Obstructive Pulmonary Disease (COPD), and cancer.

Career Highlights

Tony Siu has made significant strides in the pharmaceutical industry, having worked with renowned companies such as Merck Sharp & Dohme Corporation and Merck Canada Inc. His expertise and ingenuity have contributed to various innovative projects that prioritize health advancements.

Collaborations

Throughout his career, Siu has collaborated with notable individuals, including Michael D. Altman and Jongwon Lim. These partnerships have fostered an environment of creativity and innovation, enhancing the impact of his inventions on the healthcare industry.

Conclusion

Tony Siu's extensive patent portfolio and his dedication to research exemplify the essence of innovation in the pharmaceutical sector. His contributions continue to pave the way for future discoveries that hold the potential to improve countless lives through the development of novel treatments.

Profile summary based on public USPTO records.